Physician profile
Kay T Khine
NPI 1902239528
$16,895.10
in general payments reported to CMS, 2019-2025
25 companies · $7,946 in 2025
The $7,946 reported for 2025 was more than what 92% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $848 · 2021: $45.55 · 2022: $1,865 · 2023: $3,152 · 2024: $2,935 · 2025: $7,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,534 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,533.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $7,594.82 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Alcon Vision LLC | $2,580.73 | 2021-2025 | Clareon, Rocklatan, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $1,174.41 | 2022-2025 | Miebo, Envista Mx60 Iol, Amvisc |
| Abbvie INC. | $1,005.98 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $796.65 | 2023-2025 | Cequa |
| Lumenis Be INC | $551.34 | 2023 | M22 |
| Astellas Pharma US INC | $418.92 | 2023-2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $361.64 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $343.81 | 2022-2024 | |
| Rxsight INC | $314.37 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Allergan, INC. | $243.17 | 2020-2022 | |
| Oyster Point Pharma, INC. | $212.80 | 2024 | Tyrvaya |
| Ocular Therapeutix, INC. | $202.14 | 2024-2025 | Dextenza |
| Dompe US, INC. | $184.68 | 2023-2025 | Oxervate |
| Shockwave Medical, INC | $173.33 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $154.69 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $127.46 | 2019-2025 | Tecnis Simplicity |
| Glaukos Corporation | $82.07 | 2023-2025 | Idosetr, Photrexa Cross-Linking Kit |
| Horizon Therapeutics Plc | $73.20 | 2022 | |
| Harrow Eye, LLC | $71.72 | 2024-2025 | Vevye |
| Rayner Intraocular Lenses Limited | $60.90 | 2024-2025 | Rayone Aspheric, Rayone Emv, Rayner Cataract Set 1 |
| Thea Pharma INC. | $60.32 | 2023-2025 | Iyuzeh |
| Abiomed | $44.61 | 2023 | Impella |
| Nova Eye, INC. | $34.74 | 2024 | |
| Medline Industries LP | $26.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kay Khine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.